Monthly Archives: June 2012

Why a rat is smarter than Google

Posted on by

A rat is smarter than Google. And that's no dig at Google, according to artificial intelligence researchers Yann LeCun and Josh Tenenbaum. The two spoke at the World Science Festival in New York City after the premier of "The Creator: Alan Turing and the Future of Thinking Machines," a trippy arthouse film about 1940s and 1950s artificial intelligence visionary Alan Turing.

The galactic encyclopedia we know as Google is brilliant in many ways for the amount of information it can absorb and shoot back in response to virtually any kind of question. Still, "It's rote learning; there's no understanding," said LeCun, a professor of computer and neural science at New York University.

In terms of computational ability, even the most-powerful computers in the world are just approaching that of an insect, according to LeCun. "I would be happy in my lifetime to build a machine as intelligent as a rat," he said.

More science news from msnbc.com

What is a flame? A grad student has won the Flame Challenge with a seven-minute cartoon that explains the answer in terms that 11-year-olds would understand and actually enjoy!

And some of the seemingly amazing things that Google can do, like giving us driving or walking directions nearly instantaneously, use only a basic kind of intelligence called simple planning. "That's very easy," said Tenenbaum, a professor of computational computer science at MIT. "It's not even called it AI anymore. It's just called Google." [ How to Use the New Research Tool in Google Docs ]

Real intelligence, they said, is not just memorizing but using what you've learned to figure out situations you've never experienced, such as the film the men had just seen. "You watch this film and you see images you've never seen before. You may not know anything about the life of this character," Tenenbaum said.

"That whole context of communication intelligence, of getting inside another person just by the data of what they say and you say back, that's the heart of human intelligence," he said.

The two professors are nowhere near that. LeCun, for example, is experimenting with a driving robot that tries to identify the objects around it. He showed a video of what the robot sees how it labels objects like people, trees and roads. It generally gets them right, but often calls trees people, a patch of dirt water, a lamppost a building.

To show what AI researchers are up against, LeCun described the immensity of the human brain based on the latest, albeit very rough, estimates: 100 billion neurons make from 1,000 to 10,000 connections with other neurons and use those connections up to 100 to 1,000 times a second (a pretty high estimate). That's perhaps a quintillion 1,000,000,000,000,000,000 operations happening every second in everyone's head.

More here:

Why a rat is smarter than Google

A Rat is Smarter Than Google

Posted on by

And that's no dig at Google, according to artificial intelligence researchers Yann LeCun and Josh Tenenbaum. The two spoke at the World Science Festival in New York City after the premier of "The Creator: Alan Turing and the Future of Thinking Machines," a trippy arthouse film about 1940s and 1950s artificial intelligence visionary Alan Turing.

Originally posted here:

A Rat is Smarter Than Google

Robert Jones Joins Union Bank to Head Aerospace & Defense Unit

Posted on by

LOS ANGELES--(BUSINESS WIRE)--

Robert Jones has joined Union Bank, N.A., to head its Aerospace & Defense Group where he will lead a team of professionals providing a broad range of financing and related banking services to companies across the industry. Jones is part of Union Banks National Specialized Lending Group that provides financial expertise to commercial clients including debt financing, capital markets, depository and cash management, foreign currency and interest rate risk management, global trade, and private banking services across a broad range of industries.

Jones has more than 20 years of experience in corporate and investment banking. Prior to joining Union Bank, he was a director in the aerospace and defense team at CIT Group, and previously held similar roles at Wachovia Securities and CIBC World Markets. During his career, Jones has worked with a broad array of aerospace and defense companies, including most of the major prime contractors and original equipment manufacturers, and many of their supply chain partners, both in the U.S. and overseas. He has also worked extensively with investment bankers and private equity investors focused in this sector.

We are thrilled to welcome Robert to Union Bank and know that his deep experience in this unique industry will provide solid counsel and knowledge to our clients, and help us expand our outreach to this broad and growing sector of the economy, said Executive Vice President Bita Ardalan, head of the National Specialized Lending Group.

Jones received his bachelors degree from the University of Western Ontario, and is a Chartered Financial Analyst.

About UnionBanCal Corporation & Union Bank, N.A.

Headquartered in San Francisco, UnionBanCal Corporation is a financial holding company with assets of $92.3 billion at March 31, 2012. Its primary subsidiary, Union Bank, N.A., is a full-service commercial bank providing an array of financial services to individuals, small businesses, middle-market companies, and major corporations. The bank operates 407 branches in California, Washington, Oregon, Texas, New York and Illinois, as well as two international offices. UnionBanCal Corporation is a wholly-owned subsidiary of The Bank of Tokyo-Mitsubishi UFJ, Ltd., which is a subsidiary of Mitsubishi UFJ Financial Group, Inc. Union Bank is a proud member of the Mitsubishi UFJ Financial Group (MUFG, NYSE:MTU), one of the worlds largest financial organizations. Visit http://www.unionbank.com for more information.

Link:

Robert Jones Joins Union Bank to Head Aerospace & Defense Unit

Eclipse Aerospace starts production on Eclipse 550

Posted on by

Eclipse Aerospace announced the official launch of production for its Eclipse 550 very light jet.

The company has an established supply chain, new Federal Aviation Administration production certification and a certified airframe, according to information from Eclipse.

Deliveries are to begin in mid-2013.

Eclipse plans for initial low-volume production with full production in 2014 for 50 to 100 planes a year, depending on market demand.

Eclipse was founded in 1998 by former Microsoft employee Vern Raburn; Bill Gates was a major stockholder.

The company produced 259 Eclipse 500 jets before it entered Chapter 11 bankruptcy in November 2008. That converted to Chapter 7 liquidation in early 2009.

After a lengthy bankruptcy, one bidder, Eclipse Aerospace Inc., headed by Mike Press and Mason Holland, bought the assets out of the company.

New production of the Eclipse Jet, that was the ultimate goal of EAI when we started the process two and a half short years ago, Mason Holland, Eclipse Aerospace chairman and CEO, said in a statement.

Besides announcing production of the Eclipse 550, Eclipse also announced the Eclipse International Dealer organization. Dealers representing more than 30 countries have signed agreements to buy Eclipse 550 jets scheduled for delivery in 2014 and early 2015, the company said.

The Eclipse 550 twin-engine jet is built on the Eclipse 500 model, but includes updated aircraft systems, such as auto-throttles, synthetic vision, enhanced vision and a redundant flight management system.

Continued here:

Eclipse Aerospace starts production on Eclipse 550

Leading Anti-Cancer Drugs and Associated Market 2012-2022

Posted on by

NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Leading Anti-Cancer Drugs and Associated Market 2012-2022

http://www.reportlinker.com/p0819459/Leading-Anti-Cancer-Drugs-and-Associated-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

Cancer treatments - discover which products have greatest potential

Where are cancer-treating drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.

This study investigates leading drugs to treat human cancers. It lets you assess potential sales trends at world market, therapeutic submarket, product and national level to 2022.

How will 25 leading products - including Avastin, Rituxan, Herceptin and Glivec/Gleevec - perform from 2012? See potential revenues and other information. The study also assesses eight recently approved drugs.

Our investigation gives you business research and analysis with sales forecasts. You also see forecasting of five submarkets to 2022, finding potential revenues:

Traditional antineoplastic agents

Read more here:
Leading Anti-Cancer Drugs and Associated Market 2012-2022

Forsyth Tech Expands Nanotechnology Educational Leadership in North Carolina Through NanoProfessor Nanoscience …

Posted on by

SKOKIE, IL--(Marketwire -06/04/12)- NanoProfessor, a division of NanoInk, Inc. focused on nanotechnology education, announced today that Forsyth Technical Community College (Forsyth Tech) is expanding its nanotechnology educational leadership in North Carolina by integrating the NanoProfessor Nanoscience Education Program into its current nanotechnology curriculum. Students will have the opportunity to work with NanoInk's NLP 2000 Desktop NanoFabrication System, the first desktop nanofabrication system allowing students to quickly and easily build custom-engineered nanoscale structures with a wide variety of materials from biomolecules to metal nanoparticles using NanoInk's proprietary Dip Pen Nanolithography (DPN).

Forsyth Tech's two-year Associate of Applied Science in Nanotechnology degree is the only one of its kind with graduates in the American Southeast. Classes are held in the rapidly expanding Piedmont Triad Research Park in downtown Winston-Salem. The college is also home to one of the largest biotechnology programs in the state.

"The NanoProfessor Program will not only enhance our existing nanotechnology curriculum, but it will enable students to conduct new, exciting hands-on lab experiments with NanoInk's NLP 2000 Desktop Nanofabrication System," said Kevin Conley, Program Coordinator of Nanotechnology Education at Forsyth Tech. "By expanding the skills and experience of our students as they work at the nanoscale, we will provide them with a competitive advantage for the rapidly growing number of nanobiotechnology jobs in North Carolina."

"We are extremely pleased that Forsyth Tech, a recognized leader in nanotechnology education, has selected the NanoProfessor Nanoscience Education Program to complement its already impressive nanotech curriculum," said Dean Hart, Chief Commercial Officer at NanoInk. "By training a nano savvy workforce, Forsyth Tech will not only help the state of North Carolina accomplish its mission of being a global leader in nanotechnology, but will also help the U.S. maintain leadership in the growing global nanotech market."

"Forsyth Tech and NanoProfessor are globally recognized for their pioneering work in nanotech education," said Griffith A. Kundahl, Executive Director of the Center of Innovation of Nanobiotechnology. "This announcement is great news for North Carolina which depends on an educated nanotech workforce to maintain its position as one of the strongest nano clusters in the world."

The NanoProfessor Nanoscience Education Program aims to expand hands-on nanotechnology education from the cleanrooms of research-based universities to the classrooms of undergraduate institutions, and is especially well-suited to nanotechnology educational initiatives at the community college, technical institute, and undergraduate university level. Alternating between classroom lectures and hands-on labs, the NanoProfessor Program provides students with the opportunity to learn the fundamentals for building custom-engineered nanoscale structures while working with state-of-the-art equipment including NanoInk's NLP 2000 Desktop NanoFabrication System, a student-friendly atomic force microscope, an advanced fluorescence microscope, a nanoparticle characterization instrument, and various chemical and biological materials used today within current and emerging nanotechnology applications.

Forsyth Tech, based in Winston-Salem, N.C., is one of the largest community colleges in the state and provides students with exceptional technical education and training, as well as college transfer, adult basic education, and continuing and corporate education programs. The college responds to student, employer, and community needs with innovative, flexible programs and service delivery. The Nanotechnology Degree Program is founded on the six pillars of Nanotechnology: Biology, Chemistry, and Physics, as well as Engineering, Economics, and Ethics. Program Coordinator of Nanotechnology Kevin Conley can be reached at kconley@forsythtech.edu or (336)734-7389. More information on the college is available at: http://www.forsythtech.edu.

Nanotechnology is the understanding and control of matter at dimensions between approximately one and 100 nanometers (nm), where unique phenomena enable novel applications not feasible when working with bulk materials. A nanometer is one-billionth of a meter. Encompassing nanoscale science, engineering, and technology, nanotechnology involves imaging, measuring, modeling, and manipulating matter at the nanoscale. A study funded by the National Science Foundation projects that six million nanotechnology workers will be needed worldwide by 2020, with two million of those jobs in the United States. However, as of 2008, there were only 400,000 estimated workers worldwide in the field of nanotechnology, with an estimated 150,000 of those in the United States.

About the NanoProfessor Nanoscience Education Program The NanoProfessor Nanoscience Education Program aims to advance undergraduate nanotechnology education and address the growing need for a skilled, nano-savvy workforce. The NanoProfessor Program, including instruments, an expert-driven curriculum, and student/teacher support materials, is available for high schools, community colleges, technical institutes, and universities worldwide. More information is available at http://www.NanoProfessor.net or (847)679-NANO (6266). You can also like NanoProfessor on Facebook at http://www.facebook.com/NanoProfessor1 and follow on Twitter at http://www.twitter.com/nanoprofessor1.

NanoInk, NanoProfessor, the NanoProfessor logo, Dip Pen Nanolithography, and DPN are trademarks or registered trademarks of NanoInk, Inc.

Follow this link:
Forsyth Tech Expands Nanotechnology Educational Leadership in North Carolina Through NanoProfessor Nanoscience ...

Humble genius earns medical degree at 21

Posted on by

June 3, 2012 (CHICAGO) (WLS) -- He was an accomplished pianist at age 9. Now at 21, Sho Yano is the youngest medical school graduate in the history of the University of Chicago.

Sho earned his degree from the Pritzker School of Medicine and is about to enter a residency in pediatric neurology.

"It feels like a nice little accomplishment," Sho said. "I want to go on and do something bigger. I don't want to act like there is some particular reason I should make a great discovery versus any of my classmates so far."

Sho is a genius whose I.Q. is beyond what an I.Q. test can measure. He was reading at 2, composing music at 5 and as a very focused 9-year-old, entered Loyola University.

"I came to college to study, not to hang out or date," he said in 2000 when he entered Loyola.

Studying is exactly what he did. Sho said academics were easy; dealing with discrimination was the real learning experience.

"I ran into things like people shouting 'go back to elementary school' on campus," Sho said.

Being socially accepted at such a young age was easier while getting his PhD and medical degree at the University of Chicago.

Sho has always been a role model for his younger sister Sayuri. She is 15 years old, an accomplished violinist and attends John Hopkins University.

The Yano siblings say the pressure to do great things comes from within.

Read more from the original source:
Humble genius earns medical degree at 21

He's the real-life Doogie Howser! Meet the 21-year-old who started college at nine and is set to graduate from medical …

Posted on by

By Daily Mail Reporter

PUBLISHED: 08:16 EST, 4 June 2012 | UPDATED: 10:34 EST, 4 June 2012

A 21-year-old Chicago man who began college at age nine and medical school three years later is about to become the youngest student ever awarded an M.D. by the University of Chicago.

Sho Yano, who was reading at age two, writing at three and composing music at five, will graduate this week from the Pritzker School of Medicine, where he also received a Ph.D. in molecular genetics and cell biology.

Yano earned his undergraduate degree from Loyola University at age 12, finishing in three years and graduating summa cum laude, the Chicago Tribune reported on Sunday.

Then and now: Sho Yano in 2000 (left) when studying at Loyola University and today (right)

The average age of students entering medical school in the U.S. is 23, and there were schools that refused Yano admittance because of his age.

School officials worried that the rigors of medical school would hinder Yano's ability to have a normal adolescence.

'I never understood that,' Yano said. 'Why would being allowed to challenge yourself be considered more damaging that being totally bored?'

Read this article:
He's the real-life Doogie Howser! Meet the 21-year-old who started college at nine and is set to graduate from medical ...

New Comprehensive Pain Management Program Offered at Beverly Hospital at Danvers Addresses Significant Health Problem

Posted on by

DANVERS, Mass.and BEVERLY, Mass., June 4, 2012 /PRNewswire/ --Pain affects nearly everyone at some point in their lives, and, in the worst cases, diminishes quality of life and livelihood. In fact, pain is a significant health problem affecting more than 100 million people and costing society at least $560-$635 billion annually in both health care and lost productivity costs.* Now research shows that pain patients do better with a comprehensive approach to care that addresses the needs of the whole person, body and mind -- combining clinical and integrative therapies. That is why Beverly Hospital at Danvers Pain Management Center is launching a new integrated model of care offering not only traditional state-of-the-art pain medication and injection services, but a range of behavioral health, physical and integrative medicine treatments to help patients with acute and chronic pain.

The new care model offers a full complement of pain medicine services, including the latest pain injection therapies, medications and medication management, physical therapy, psychotherapy, and addiction counseling as well as integrative therapies, such as acupuncture, Reiki and massage therapy in a custom-designed care plan for patients.

"We have created this multi-specialty center so that our patients have the very best treatment options, since we now know that pain patients do best when treated in this kind of comprehensive treatment environment," says Dr. Kenneth Branton, medical director of the Pain Management Center. "I'm very excited about our ability to offer this level of care and services," he says.

The Pain Center's multi-disciplinary team includes physician specialists in pain medicine, neurosurgery, and physiatry; a nurse practitioner; behavioral health and addiction/psychiatry specialists; and physical therapists, as well as Reiki therapy, acupuncture and massage therapy services.

An estimated 116 million people in the US experience acute or chronic pain each year, and more people suffer from pain than from leading diseases combined, including heart disease, cancer and diabetes, according to the American Academy of Pain Management. Pain can be the result of injury or disease, but it can also be the disease itself, as in the case of neuropathic pains or headaches. And, pain exacts a heavy toll on the individual."Pain adversely affects a person's quality of life, causing him or her to have difficulty with activities of daily living, such as cooking, cleaning, and dressing. And, it can cause depression and anxiety and interfere with job performance and interpersonal relationships," says. Branton.

Dr. Anthony LoMonaco, who is double board certified in anesthesia and pain management, feels that patients suffering from pain need to have an active role in the management of their pain."Developing coping skills can help change the way a person responds to and manages pain. Coping is a very important step in feeling physically and emotionally better sooner," says LoMonaco, who adds that maintaining a healthy lifestyle is extremely important for pain just as it is for heart disease and diabetes.Pain patients need to be mindful of proper diet, exercise, and smoking cessation.

Amber Dewey, RN, NPC, the center's nurse practitioner agrees. The goal of the program is to offer patients the best chance for getting back to their lives with as little pain as possible, using multiple strategies for pain prevention and management, she says. She says, "A large part of my job is coordinating the various aspects of the treatment plan, and working with the patient every step of the way."In addition to specializing in pain management, Dewey is an expert in medications management, and is well versed in the use and misuse of narcotics.

Read the original post:
New Comprehensive Pain Management Program Offered at Beverly Hospital at Danvers Addresses Significant Health Problem

Online, fun and immortality

Posted on by

I recently bumped into a cute story that seemed familiar. It suggested a switch to an 18-cent coin. I found it by way of Hacker News for my money ($0), the best news aggregator for the tech set. It was a fairly typical blog post: a summary of a paper that ran the math and determined that the average number of coins one gets from a cash register is 4.7. But the addition of an 18-cent coin would drop that to 3.89.

I like this sort of thing. Its quirky. Its math. It speaks to the stupidity of pennies. It makes me think about government inefficiencies and the very human affection for little hunks of inconvenient metal.

But I couldnt get past the familiarity. I reread the article and realized it was originally written in 2003. Hacker News usually is pretty current, but a story like this is sort of timeless and prone to resurgence.

Then I realized the byline was Roland Piquepaille, and you dont forget a name like that. For many years, Roland was incredibly active on Slashdot, the news website I founded. His submissions were often like this 18-cent-coin piece: off the beaten path and interesting.

Roland died on Jan. 6, 2009. Apparently, last week, somebody searched online for something or other and landed on a story nearly a decade old, written by a man who had been dead for more than three years; it hit the Internet again just as effectively as if it were written yesterday. A trivial but fun little story has a bit of immortality attached to it.

Roland took a lot of garbage from Slashdot readers over the years. He was incredibly effective at what he did, and his name appeared on the site a lot. A community has a habit of being hostile toward anything extreme, and Roland often submitted stories on the fluffier end of the news spectrum. And he succeeded a lot, which made him a target. That always made me a little sad.

But Id like to think he gets the posthumous last laugh. He found fun stuff that we enjoyed reading. I hope that the traces I leave behind after Im gone are still good for the occasional laugh as well. Ill never write the Great American Novel or direct an Oscar-winning film. But the Internet lets all of us live forever.

Rob Malda is chief strategist and editor at large for the Washington Posts WaPo Labs team. Under the pseudonym "CmdrTaco," he created the "news for nerds" website Slashdot.org.

Read more here:
Online, fun and immortality

Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment

Posted on by

DEERFIELD, Ill.--(BUSINESS WIRE)--

Baxter International Inc. (BAX) today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chathams gene therapy technology.

The collaboration will allow Baxter to investigate Chathams Biological Nano ParticlesTM (BNP), an advanced recombinant adeno-associated virus-(rAAV) based gene therapy technology that has shown potential therapeutic benefit in early clinical studies. A small independent study involving six patients using Chatham technology components was the topic of a 2011 article in The New England Journal of Medicine.i This agreement will involve the next generation of this gene therapy technology, which Baxter and Chatham will investigate through U.S.-based hemophilia B clinical trials. Baxter has obtained global rights for the marketing and commercialization of the new treatment.

''This collaboration demonstrates Baxters ongoing commitment to scientific innovation in advancing treatment options for patients living with hemophilia. This initiative complements Baxters extensive hemophilia portfolio and helps to address unmet needs of hemophilia patients,'' said Ludwig Hantson, Ph.D., president of Baxters BioScience business.

Baxter made a $25 million upfront cash payment for the development and advancement of the program through early clinical trials, and will record this amount as a special pre-tax in-process research and development charge in the second quarter of 2012. Baxter may make additional payments over the next several years based on certain development and commercial milestones.

''This agreement initiates a clinical development collaboration dedicated to advancing a potential long-term treatment paradigm for hemophilia patients. We look forward to working with Baxter and view this transaction as the optimal path toward providing a sustainable therapeutic to a worldwide patient population,'' said Jade Samulski, Vice President at AskBio and Co-Founder of Chatham Therapeutics.

Hemophilia B is the second most common typeof hemophilia (also known as Christmas disease) and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding.ii Hemophilia B occurs in about one in 25,000 males, with approximately 4,000 people in the United States currently diagnosed with the disease.iii Hemophilia B is often a debilitating, chronic disease with complications that include bleeding episodes, hemophilic arthropathy (bleeding into a joint) and hospitalization.iv

Baxter is pursuing a number of research opportunities in hemophilia. The company is conducting a Phase I/III clinical trial of BAX326, a recombinant Factor IX being evaluated for the treatment of patients with hemophilia B, and expects to file for U.S. approval by the end of 2012.

About Baxter International Inc.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

More here:
Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment

Chemistry 101: Playing together their whole lives, 9 seniors lead Dragons to states

Posted on by

They do everything together, including win Warren Area High School's first District 10 baseball championship since 1977.

There were nine seniors on the field to start the Dragons' 2-0 win over Cathedral Prep last Monday in the District 10 Class AAA championship game at Ainsworth Field in Erie.

Catcher-Andrew Bevevino; first baseman-Preston McMeans; second baseman-Eddie Dorunda, shortstop-Kory Thomas; third base-Kevin VanOrd; left fielder-Dan Maeder; center fielder-Chris Danielson; right fielder-Matt Jaskolka, and; pitcher-Hank Morrison.

All seniors.

"Nine starters - we've never had that many (seniors start) before," said Warren head coach Jeff Passaro.

Now those nine seniors will lead the Dragons into the PIAA Class AAA Tournament against Thomas Jefferson at 6 p.m. Monday at Slippery Rock University.

And call it what you will, but there's a definite chemistry with a group of boys that have been hanging out together their entire lives.

"I know them better than I know anyone," said Bevevino.

On and off the field.

"It makes it a ton easier," said Morrison. "I can throw anything I want to (to Andrew) because I trust him. He's been a catcher his whole life, and I think it makes a big difference with the chemistry."

Here is the original post:
Chemistry 101: Playing together their whole lives, 9 seniors lead Dragons to states

Understanding the chemistry of love

Posted on by

INTOUCH

A mismatch in libidos can doom a marriage. Understanding the chemistry of love can help mismatched partners enjoy a healthier, happier relationship.

One of the questions I'm asked most frequently concerns couples with mismatched libidos, where a husband wants sex much more often than his wife. "Does he really love me, or does he just want sex?" is a wife's common reaction. At the same time, a man can become very frustrated trying to find the answer to "Why does she always refuse me? Doesn't she love me anymore?" At first glance, many people might consider this situation as a trivial issue hardly worth arguing over (at least among conservative Thais). But for many couples, the mismatch wreaks plenty of marital havoc.

Intimacy is one area of significant differences between men and women. Generally, a woman needs to form an emotional connection to her partner in order to feel ready for sexual activity.

For a man, sex is necessary to create an emotional connection to his partner. This helps explain why husbands typically need sex more often than wives. However, to more fully appreciate the differences, it's important to know how hormones shape the different behaviours of men and women.

RELATIONSHIP CHEMISTRY

Many people misunderstand the role of hormones; they tend to believe hormones are only related to cancer or sex. In fact, hormones are chemical messengers that travel throughout the body coordinating complex processes, including growth and development, metabolism, fertility, and most other functions the body relies on to stay alive and healthy. Hormones also play a key role in puberty-related changes and immune system health, and they can affect individual behaviour.

Our libido, or sex drive, is included in the functions controlled by hormones. I'd like to look now at the specific hormones that affect libido.

TESTOSTERONE

Testosterone, the main male hormone, is produced primarily by the testicles; it plays a key role in male puberty and reproduction and is powerful enough to boost a man's libido in very little time. Testosterone is also referred to as a sex hormone since it affects both male and female sex drive.

Original post:
Understanding the chemistry of love

Rangers' chemistry helps them fight back

Posted on by

ANAHEIM -- Michael Young understands the fragile psyches of fans. He didn't need to be told there were growing concerns deep in the hearts of Texans as the Angels -- these remodeled Albert Pujols, C.J. Wilson Angels -- rose from their April slumber and began making threatening noises.

Victories in the first two games of a June weekend series at Angel Stadium presented manager Mike Scioscia's troupe with the opportunity on Sunday for a sweep that would shave the Rangers' American League West lead to 2 1/2 games.

Drawing on its inner reserves and deep resources, Texas muzzled Pujols in the game's most compelling moment and went on to whack his new club, 7-3. The lead is 4 1/2-games.

"I'm a fan," said Young, who grew up in the Los Angeles area cheering for the local teams but has become attached to the Cowboys since his Raiders returned for Oakland. "I watch the Lakers and Cowboys, and they lose, and there's a beer on the floor, some chips on the floor. I'm not happy.

"So I can take a step back and see how they feel about us. Our fans are emotionally invested in us, and we certainly appreciate that. They're all in. But there's a difference. It's easier for us because we can control it and move forward."

The Rangers took control on Sunday, but not until Dan Haren managed to string out their weekend frustration by stranding seven runners in five innings. The Rangers led 2-1 when Haren, his pitch count at 104, departed.

It would have been tied, if Pujols at first base had handled a one-hopper by Young that scooted past his back hand for a two-out, run-scoring single in the fifth. It brought home Ian Kinsler, who'd doubled leading off the inning.

"It's tough to see on the corners here in the daylight, on a bright day like this," Young said. "That's a tough play for Albert. He's holding the runner [Adrian Beltre] on, and he doesn't expect a right to hit a ball like that."

Young's second hit, a line-drive single to left, would be followed by a monstrous home run by Nelson Cruz in the seventh against Bobby Cassevah for a 5-2 lead. Given the 3-0 green light by manager Ron Washington, Cruz launched it an estimated 484 feet -- longest of the season and 11th longest since 2006 according to ESPN STATS & INFO.

"That's the farthest I've seen in this park," said Texas shortstop Elvis Andrus, who made dazzling plays deep in the hole, robbing Erick Aybar and Mark Trumbo, behind starter Matt Harrison and reliever Mike Adams. "Nelson and Josh [Hamilton] and Beltre are the only ones who can do it."

The rest is here:
Rangers' chemistry helps them fight back

Lando & Anastasi, LLP Expands Biotechnology/Pharmaceutical and Electrical/Computer Patent Teams

Posted on by

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Lando and Anastasi, LLP (L&A) today announced that Julie Gottselig, Dominic Yee, and Austin Kim have joined the firm.

The Cambridge-based intellectual property law firm, one of the largest IP firms in New England, continues its steady growth in response to strong client demand for high quality and responsive intellectual property legal services. The L&A biotechnology and pharmaceutical practice will expand with the addition of Julie Gottselig and Dominic Yee; and Austin Kim will join the firms electrical and computer science practice.

Julie Gottselig is an Associate at L&A. She focuses her practice on patent prosecution and counseling in the areas of biotechnology, pharmaceuticals, molecular biology, biochemistry, medical devices, and related fields. Prior to joining L&A, she was an Associate at McCarter & English, LLP in Boston. Julie is registered to practice before the United States Patent and Trademark Office.

Julie graduated from New England School of Law, summa cum laude, where she was the valedictorian of her class and recipient of the Dean Arthur W. MacLean Award for academic excellence. She received a Ph.D. in Neuroscience from the University of Iowa; she completed her post-doctoral fellowship at Harvard Medical School and Brigham & Womens Hospital; and she was a post-doctoral researcher at the Institute of Pharmacology & Toxicology, University of Zurich. Julie received her B.A. in Psychology from Colorado College. Prior to entering intellectual property law, Julie authored numerous peer-reviewed scientific research articles published in leading journals, and has received several research awards, including postdoctoral fellowship awards from the National Institute of Mental Health and the National Heart, Lung, and Blood Institute.

Dominic Yee is a Technology Specialist at L&A, and focuses his practice on patent prosecution, diligence and counseling in the areas of areas of biotechnology, pharmaceuticals, and chemistry.

Dominic received a Ph.D. in Chemistry from Columbia University, and he completed his post-doctoral fellowship with Nobel laureate Roger Tsien at the Howard Hughes Medical Institute at University of California San Diego (UCSD). Dominic received his B.S. in Chemistry and Biochemistry, magna cum laude, from UCSD. He attends Suffolk University Law School. Prior to entering intellectual property law, Dominic was a Scientist at Vertex Pharmaceuticals, where he worked on solid dosage form development and drug delivery technologies.

We are excited that Julie and Dominic have joined the life sciences team at L&A, and welcome the technological expertise they bring to both the biological and chemical aspects of our practice, commented Louis Myers, a Partner at the firm.

Austin Kim is an Associate at L&A. He focuses his practice on patent prosecution in the areas of computer science, electrical engineering, mechanical engineering, and medical devices. Prior to joining L&A, he was an Associate at Fish & Richardson in Boston. Austin is registered to practice before the United States Patent and Trademark Office.

Austin graduated from Boston College Law School. He received an M.Eng. and S.B. in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.

Read more from the original source:
Lando & Anastasi, LLP Expands Biotechnology/Pharmaceutical and Electrical/Computer Patent Teams

Global Markets for Media, Sera and Reagents in Biotechnology — Focus on Emerging Markets

Posted on by

NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0870808/Global-Markets-for-Media-Sera-and-Reagents-in-Biotechnology----Focus-on-Emerging-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

INTRODUCTION

This report explores present and future strategies within the media and sera market, including reagents used in biotechnology. The improvisation of the market, the setbacks and the needs of the market are discussed in this report. The types of cell cultures and the products from cell culture technology are also presented in this report. The advantages and disadvantages for the use of various types of media are also covered in this report.

A detailed analysis of the cell culture industry structure has been conducted. This includes the biotechnology reagents, media and the sera used. Revenues are broken down by global region. Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for the cell culture industrymedia, sera and reagents used in biotechnologyare also discussed in the report, with an emphasis on the usage in the research, production and contract segments. The report also covers significant patents in each segment.

REASONS FOR DOING THIS STUDY

Demand for cell culture products, namely media, sera and reagents, is increasing, with the increasing demand for biopharmaceuticals. Cell culture, a crucial component of the life sciences industry, has witnessed major development during the past three decades. R&D spending, along with increasing competition, patent expiries, new technologies and an international marketplace are moving the cell culture process in a new direction. As cell culture technologies evolved, a number of disciplines such as cell biology, genetic engineering, protein chemistry, genomics and chemical engineering have been successfully incorporated into the cell culture field.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of the different types of media used in light of the new technologies, growing competition and changing customer needs.

The lead consultant for this project was Dr. Kapil A. Setia, who holds a doctoral degree in the life sciences. She has a number of research publications to her credit.

Continued here:
Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on Emerging Markets

Global Markets for Media, Sera and Reagents in Biotechnology — Focus on Asia

Posted on by

NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on Asia

http://www.reportlinker.com/p0870807/Global-Markets-for-Media-Sera-and-Reagents-in-Biotechnology----Focus-on-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

INTRODUCTION

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for media, sera and the reagents used in biotechnology. The key objective is to present a comprehensive analysis of the current market and its future direction in the media, sera and biotechnology reagents markets as an important tool for the cell culture industry.

This report explores present and future strategies within the media and sera market, including reagents used in biotechnology. The improvisation of the market, the setbacks and the needs of the market are discussed in this report. The types of cell cultures and the products from cell culture technology are also presented in this report. The advantages and disadvantages for the use of various types of media are also covered in this report.

A detailed analysis of the cell culture industry structure has been conducted. This includes the biotechnology reagents, media and the sera used. Revenues are broken down by global region. Sales figures are estimated for the five-year period from 2011 through 2016.

Applications for the cell culture industrymedia, sera and reagents used in biotechnologyare also discussed in the report, with an emphasis on the usage in the research, production and contract segments. The report also covers significant patents in each segment.

REASONS FOR DOING THIS STUDY

The rest is here:
Global Markets for Media, Sera and Reagents in Biotechnology -- Focus on Asia

Goodwin Biotechnology and MD Anderson Cancer Center Collaborate on the GMP Manufacturing of a Fusion Protein Conjugate …

Posted on by

PLANTATION, Fla. and HOUSTON, June 4, 2012 /PRNewswire/ --Goodwin Biotechnology, Inc. (GBI) and The University of Texas MD Anderson Cancer Center jointly announce a collaboration for process development and GMP manufacturing of a fusion protein composed of a vascular endothelial growth factor (VEGF) and the recombinant toxin, Gelonin (rGel), conjugated to a DOTA chelator. The fusion protein targets the tumor neovasculature, or blood supply, and inhibits tumor growth, and the DOTA chelator facilitates the subsequent labeling with a radioisotope for diagnostic imaging and/or therapeutics.

GBI has completed process development and is readying for the GMP manufacture of the drug conjugate. The GMP manufactured drug conjugate will subsequently be radiolabeled with 64Cu and evaluated in an early stage, human clinical trial.

"Contributing to such a medical advance is exciting," noted Muctarr Sesay, PhD, Vice President of Process Development at GBI. "We have a long history of collaborating with Dr. Rosenblum and MD Anderson for GMP manufacturing of therapeutic antibody : drug conjugates that have been used in human clinical trials. With the current project, we are also leveraging our extensive experience with preparing conjugates for subsequent radioisotope labeling to develop this important product for diagnostic and therapeutic applications."

"I have worked with GBI for over 10 years producing antibody : drug conjugates, and have been impressed with their bioconjugation expertise and the service they provide," noted Michael G. Rosenblum, Ph.D. Professor of Medicine; Head, Immunopharmacology and Targeted Therapy Laboratory and Director of Research Development in the Department of Experimental Therapeutics at MD Anderson. "The conjugate we are developing will hopefully enhance our ability to detect and treat primary cancers sooner, but it may also more accurately identify and inhibit metastatic spread earlier in the course of the disease."

About Goodwin Biotechnology, Inc. Goodwin Biotechnology is a fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI has the expertise and experience in cell line development, process development and GMP manufacturing of recombinant proteins and antibodies, as well as conjugated therapeutic proteins (e.g., antibodies conjugated to linkers for radioimmune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins) by leveraging our proprietary conjugation technology. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies and a road map to meet product requirements from the milligram, gram and kilogram range as the product candidates move along the clinical approval pathway. With nearly 20 years of experience as an independent contract manufacturer, GBI has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies. For more information, please visit http://www.goodwinbio.com/.

For more information on the University of Texas M.D. Anderson Cancer Center, please visit http://www.mdanderson.org/

For more information, please contact:

Goodwin Biotechnology:

Dave Cunningham

Director of Marketing

The rest is here:
Goodwin Biotechnology and MD Anderson Cancer Center Collaborate on the GMP Manufacturing of a Fusion Protein Conjugate ...

BVU student selected for DMU health professions program

Posted on by

Chelsea Clayton, a triple biology, chemistry and biochemistry major at BVU, will be one of 10 students attending an advanced health professions summer program at Des Moines University. / submitted photo

"I am one of two students from the state of Iowa that will be participating in this program," Chelsea says. "The other eight students come from Washington, Nebraska, Illinois, Pennsylvania, Florida, California and Michigan."

This three-week program exposes students to the four advanced clinical degrees offered at DMU. All costs associated with accommodations, transportation and food are covered by DMU.

"Through this program, I will have the opportunity to learn from lectures and presentations in DMU's four clinical areas - osteopathic medicine, podiatric medicine and surgery, physical therapy and physician assistant studies," says Chelsea.

"I will also have the opportunity for hands-on experiences as well as job shadowing doctors and other care providers in the DMU clinic. On top of all that, I will learn how to plan for medical/health professions school and participate in mock interviews to enhance my preparation for medical school. I believe this program will impact my career goals by helping me decide what area of medicine I actually want to go into. It will give me the additional tools I need to get into medical school and accomplish my dream of becoming a doctor."

Chelsea learned of the opportunity from BVU faculty and says her relationships with her professors have had a major impact on her learning and career decisions.

"Aside from being exceptionally well at what they do in the classroom, BVU's professors have also encouraged me outside the classroom and I know that I am more than just 'another student' to them."

"I know that my professors truly care about me, and because of that it has motivated me to accomplish even more than what I would have anywhere else," says Chelsea.

"BVU's facilities and programs have also helped to prepare me for this program. I believe that BVU has one of the nicest science centers I have seen, and the access to the research equipment that BVU has available to students is amazing."

Read the original here:
BVU student selected for DMU health professions program